Rep. Bruce Westerman Sells Off Shares of Roche Holding AG (OTCMKTS:RHHBY)

Representative Bruce Westerman (R-Arkansas) recently sold shares of Roche Holding AG OTCMKTS: RHHBY. In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Roche stock on April 21st. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of UniCredit OTCMKTS: UNCRY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Siemens Aktiengesellschaft OTCMKTS: SIEGY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of GSK NYSE: GSK on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 4/21/2025.
• Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 4/21/2025.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Chevron NYSE: CVX on 4/21/2025.

Roche Trading Up 1.6%

Shares of OTCMKTS RHHBY traded up $0.63 during midday trading on Monday, hitting $39.03. The company's stock had a trading volume of 1,891,819 shares, compared to its average volume of 2,997,473. The business's 50 day moving average is $40.04 and its two-hundred day moving average is $38.59. Roche Holding AG has a 12-month low of $31.19 and a 12-month high of $44.31. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RHHBY. Beck Mack & Oliver LLC bought a new stake in Roche during the first quarter valued at about $232,000. Corient IA LLC bought a new position in shares of Roche during the 1st quarter worth approximately $616,000. FCA Corp TX purchased a new position in Roche in the first quarter worth $494,000. Atlas Capital Advisors Inc. acquired a new position in shares of Roche during the first quarter worth $140,000. Finally, Everett Harris & Co. CA acquired a new stake in shares of Roche in the 1st quarter worth $445,000.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on RHHBY shares. Sanford C. Bernstein upgraded Roche to a "strong-buy" rating in a research report on Thursday, January 30th. HSBC downgraded shares of Roche from a "buy" rating to a "hold" rating in a research note on Monday, April 28th. Hsbc Global Res lowered Roche from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. UBS Group upgraded Roche from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, Morgan Stanley assumed coverage on Roche in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold".

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.